Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion.

Blood. 1989 Jul;74(1):388-94. Unique Identifier : AIDSLINE MED/89323366
Chen YC; Wang CH; Su IJ; Hu CY; Chou MJ; Lee TH; Lin DT; Chung TY; Liu CH; Yang CS; Department of Laboratory Medicine, National Taiwan University; Medical School, Taipei, Republic of China.

Abstract: Among 354 adult patients with either hematological malignancy or aplastic anemia, eight were positive for anti-HTLV-I antibodies; six of eight had received multiple transfusions. There was an approximately 3.5-fold increase (P less than .001) of HTLV-I seropositivity in the patients with hematologic disease (8 of 354, 2.23%) compared to the healthy adults older than 20 years (34 of 5252, .65%). Two hematological patients, one with Hodgkin's disease and one with acute promyelocytic leukemia, were found to be positive for HTLV-I, and developed and died of adult T-cell leukemia/lymphoma (ATL) subsequently. Both were long-term survivors of the primary disease and had received multiple transfusions. The latent period from blood transfusion to onset of ATL was 6 months and 11 years, respectively. Immunocompromised patients, who were seropositive for HTLV-I, may be at increased risk for ATL compared to healthy carriers of HTLV-I, and the latent period may be shorter.
Keywords: Antibodies, Viral/ANALYSIS Blood Transfusion Blotting, Southern Case Report DNA, Neoplasm/GENETICS DNA, Viral/GENETICS Female Human HTLV-I/IMMUNOLOGY Leukemia/*COMPLICATIONS/THERAPY Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*MICROBIOLOGY Lymphoma/*COMPLICATIONS/THERAPY Male Support, Non-U.S. Gov't Time Factors JOURNAL ARTICLE

KWDantibodies,viral/analysisbloodtransfusionblotting,southerncasereportdna,neoplasm/geneticsdna,viral/geneticsfemalehumanhtlv-i/immunologyleukemia/KWDcomplications/therapyleukemia-lymphoma,t-cell,acute,htlv-i-associated/KWDmicrobiologylymphoma/KWDcomplications/therapymalesupport,non-uKWDsKWDgov'ttimefactorsjournalarticle
891130
M89B0537

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .